Oragenics Past Earnings Performance

Past criteria checks 0/6

Oragenics has been growing earnings at an average annual rate of 4.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 28.9% per year.

Key information

4.6%

Earnings growth rate

36.7%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate28.9%
Return on equity-648.8%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Oragenics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0A64 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-2070
30 Jun 240-2060
31 Mar 240-2060
31 Dec 230-2150
30 Sep 230-1050
30 Jun 230-1240
31 Mar 230-1340
31 Dec 220-1440
30 Sep 220-1450
30 Jun 220-1540
31 Mar 220-1550
31 Dec 210-1650
30 Sep 210-185-19
30 Jun 210-186-15
31 Mar 210-265-4
31 Dec 200-2650
30 Sep 200-26422
30 Jun 200-25421
31 Mar 200-17413
31 Dec 190-16412
30 Sep 190-15411
30 Jun 190-15410
31 Mar 190-1347
31 Dec 180-1146
30 Sep 180-1045
30 Jun 180-834
31 Mar 180-734
31 Dec 170-734
30 Sep 170-845
30 Jun 170-844
31 Mar 170-845
31 Dec 160-845
30 Sep 160-844
30 Jun 160-834
31 Mar 160-1339
31 Dec 150-1239
30 Sep 150-1138
30 Jun 150-1037
31 Mar 151-533
31 Dec 141-633
30 Sep 141-8510
30 Jun 141-16710
31 Mar 141-16710
31 Dec 131-1689

Quality Earnings: 0A64 is currently unprofitable.

Growing Profit Margin: 0A64 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0A64 is unprofitable, but has reduced losses over the past 5 years at a rate of 4.6% per year.

Accelerating Growth: Unable to compare 0A64's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0A64 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 0A64 has a negative Return on Equity (-648.76%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 12:57
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oragenics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Theodore O'NeillAscendiant Capital Markets LLC
Keith MarkeyGriffin Securities